TGNA:FRA
Transgene SA
€०.६७
arrow_downward
-०.१५%(-०.००१००) १ दि
१३ ऑक्टो, ८:०३:०८ AM [GMT]+२ · EUR
search
सर्व सिम्बॉल
| सिम्बॉल | किंमत | बदल | % बदल |
|---|
insights_autoTGNA साठी टॉप इनसाइट जनरेट करत आहे...
उघडा
€०.६७
उच्च
€०.६७
कमी
€०.६७
मार्केट कॅप
१९.१९ कोटी
सरासरी उलाढाल
०.००
उलाढाल
०.००
५२ आठवड्यांतील उच्चांक
€१.४८
५२ आठवड्यांतील नीचांक
€०.६०
EPS
-€०.१७
कर्मचाऱ्यांची संख्या
१५२
उघडा
€०.६७
उच्च
€०.६७
कमी
€०.६७
मार्केट कॅप
१९.१९ कोटी
सरासरी उलाढाल
०.००
उलाढाल
०.००
५२ आठवड्यांतील उच्चांक
€१.४८
५२ आठवड्यांतील नीचांक
€०.६०
EPS
-€०.१७
कर्मचाऱ्यांची संख्या
१५२
बातम्यांच्या स्टोरी
वेब स्रोत आणि बातमी भागीदारांकडून
Seeking Alpha
·
२४ मिनिटांपूर्वी
Mentions of inflation have ballooned for tech companies – SoFi (SP500:)
Central Oregon Daily
·
१५ मिनिटांपूर्वी
S&P 500 flat as chipmakers fall and bank earnings roll in
ChartMill
·
३८ मिनिटांपूर्वी
What's going on in today's session: S&P500 most active stocks
Bloomberg.com
·
४ तासांपूर्वी
S&P 500 Record Rally Meets Risk of Peaking Earnings Growth
प्रोफाइल
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Transgene SA बद्दल